Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Scotia seeks FDA approval for Foscan PDT

Oct. 4, 1999

Genzyme Molecular Oncology licenses antisense cancer rights to Hybridon

Oct. 4, 1999

Cancer patients being enrolled at UNC for new trial evaluating third-generation SERM

Oct. 1, 1999

Pharma Mar presents phase I findings for ecteinascidin 743 at scientific forum

Oct. 1, 1999

Cell Genesys enters cancer gene therapy collaboration with Rigel

Oct. 1, 1999

Texas A&M describes important new class of agents for breast cancer

Sep. 30, 1999

New antitumor compounds from Schering-Plough act by inhibiting protein farnesyltransferase

Sep. 30, 1999

Long-term efficacy and tolerability reported for MTX-HSA in preliminary clinical testing

Sep. 30, 1999

Northwest Biotherapeutics and Battelle form prostate cancer collaboration

Sep. 30, 1999

Cell Pathways and RPR to study Aptosyn in combination with Taxotere

Sep. 30, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...